Oncologic Interventions: Periprocedural Medications

Abstract

Significant advances in ablative and endovascular therapies have allowed interventional radiology to play a substantial role in the management of patients with malignant neoplasms. The evolution of these procedures and the optimization of patient outcomes and experience must take into account various elements of the periprocedural period. Some of the most important considerations within the periprocedural period are the pharmacologic agents used to avoid infectious complications, decrease pain, and manage side effects. In this article, we discuss some of the most commonly used medications in interventional oncology procedures including antibiotics, narcotics, sedatives, antiemetics, and others.

Keywords

interventional oncology - interventional radiology - pharmacology - periprocedural medication - antibiotic prophylaxis - postembolization syndrome

Publication History

Article published online:
17 November 2022

• References

• 1 Khan W, Sullivan KL, McCann JW. et al. Moxifloxacin prophylaxis for chemoembolization or embolization in patients with previous biliary interventions: a pilot study. AJR Am J Roentgenol 2011; 197 (02) W343-W345
• 2 Watchmaker JM, Lipnik AJ, Fritsche MR. et al. Are prophylactic antibiotics necessary prior to transarterial chemoembolization for hepatocellular carcinoma in patients with native biliary anatomy?. J Surg Oncol 2018; 117 (06) 1312-1317
• 3 Wang J, He XD, Zhang YC. Antibiotic prophylaxis in transarterial therapy of hepatocellular carcinoma: a meta-analysis. Can J Gastroenterol 2012; 26 (02) 85-91
• 4 Chehab MA, Thakor AS, Tulin-Silver S. et al. Adult and pediatric antibiotic prophylaxis during vascular and IR procedures: a Society of Interventional Radiology practice parameter update endorsed by the Cardiovascular and Interventional Radiological Society of Europe and the Canadian Association for Interventional Radiology. J Vasc Interv Radiol 2018; 29 (11) 1483-1501 .e2
• 5 Ryan JM, Ryan BM, Smith TP. Antibiotic prophylaxis in interventional radiology. J Vasc Interv Radiol 2004; 15 (06) 547-556
• 6 Patel S, Tuite CM, Mondschein JI, Soulen MC. Effectiveness of an aggressive antibiotic regimen for chemoembolization in patients with previous biliary intervention. J Vasc Interv Radiol 2006; 17 (12) 1931-1934
• 7 Ober MC, Hoppe-Tichy T, Köninger J. et al. Tissue penetration of moxifloxacin into human gallbladder wall in patients with biliary tract infections. J Antimicrob Chemother 2009; 64 (05) 1091-1095
• 8 Blackburn H, West S. Management of postembolization syndrome following hepatic transarterial chemoembolization for primary or metastatic liver cancer. Cancer Nurs 2016; 39 (05) E1-E18
• 9 Yang H, Seon J, Sung PS. et al. Dexamethasone prophylaxis to alleviate postembolization syndrome after transarterial chemoembolization for hepatocellular carcinoma: a randomized, double-blinded, placebo-controlled study. J Vasc Interv Radiol 2017; 28 (11) 1503-1511 .e2
• 10 Kogut MJ, Chewning RH, Harris WP, Hippe DS, Padia SA. Postembolization syndrome after hepatic transarterial chemoembolization: effect of prophylactic steroids on postprocedure medication requirements. J Vasc Interv Radiol 2013; 24 (03) 326-331
• 11 Khalaf MH, Sundaram V, AbdelRazek Mohammed MA. et al. A predictive model for postembolization syndrome after transarterial hepatic chemoembolization of hepatocellular carcinoma. Radiology 2019; 290 (01) 254-261
• 12 Bissonnette RT, Gibney RG, Berry BR, Buckley AR. Fatal carcinoid crisis after percutaneous fine-needle biopsy of hepatic metastasis: case report and literature review. Radiology 1990; 174 (3, Pt 1): 751-752
• 13 Majeed F, Porter TR, Tarantolo S, Duhachek-Stapelman A, Xie F, Elhendy A. Carcinoid crisis and reversible right ventricular dysfunction after embolization in untreated carcinoid syndrome. Eur J Echocardiogr 2007; 8 (05) 386-389
• 14 Jang S, Schmitz JJ, Atwell TD. et al. Percutaneous image-guided core needle biopsy of neuroendocrine tumors: How common is intraprocedural carcinoid crisis?. J Vasc Interv Radiol 2021; 32 (05) 745-751
• 15 Lee S, Rhim H, Kim YS. et al. Percutaneous radiofrequency ablation of hepatocellular carcinomas: factors related to intraprocedural and postprocedural pain. AJR Am J Roentgenol 2009; 192 (04) 1064-1070
• 16 Neeman Z, Wood BJ. Radiofrequency ablation beyond the liver. Tech Vasc Interv Radiol 2002; 5 (03) 156-163
• 17 Andreano A, Galimberti S, Franza E. et al. Percutaneous microwave ablation of hepatic tumors: prospective evaluation of postablation syndrome and postprocedural pain. J Vasc Interv Radiol 2014; 25 (01) 97-105 .e1, 2
• 18 Witteles RM, Kaplan EL, Roizen MF. Safe and cost-effective preoperative preparation of patients with pheochromocytoma. Anesth Analg 2000; 91 (02) 302-304
• 19 Riaz A, Awais R, Salem R. Side effects of yttrium-90 radioembolization. Front Oncol 2014; 4: 198
• 20 Bhangoo MS, Karnani DR, Hein PN. et al. Radioembolization with yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma. J Gastrointest Oncol 2015; 6 (05) 469-478
• 21 Sakamoto T, Saito Y, Kobayashi M. et al. Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin. Support Care Cancer 2020; 28 (07) 3251-3257
• 22 Sangro B, Gil-Alzugaray B, Rodriguez J. et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 2008; 112 (07) 1538-1546
• 23 Gil-Alzugaray B, Chopitea A, Iñarrairaegui M. et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 2013; 57 (03) 1078-1087
• 24 Sangro B, Martínez-Urbistondo D, Bester L. et al. Prevention and treatment of complications of selective internal radiation therapy: expert guidance and systematic review. Hepatology 2017; 66 (03) 969-982
• 25 Patel IJ, Rahim S, Davidson JC. et al. Society of Interventional Radiology Consensus Guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions - Part II: Recommendations: endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. J Vasc Interv Radiol 2019; 30 (08) 1168-1184 .e1